Immune imbalance is a critical factor in the occurrence and progression of cancers because it disrupts the immune system's ability to detect and eliminate abnormal cells. Restoring immune balance and reactivating immune cells remain major challenges in cancer immunotherapy. Current immunoregulatory strategies, such as immune checkpoint blockade, adoptive cell therapy, and therapeutic vaccines, aim to influence key immune cells, such as T cells, dendritic cells, and macrophages, to boost anti-cancer responses. However, conventional material design in immunotherapy usually emphasizes chemical composition and physical morphology, while neglecting the critical role of stereochemistry in immune cell recognition and activation.
Wang et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: